689 related articles for article (PubMed ID: 23398362)
1. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
2. Anchor-based classification and type-C inhibitors for tyrosine kinases.
Hsu KC; Sung TY; Lin CT; Chiu YY; Hsu JT; Hung HC; Sun CM; Barve I; Chen WL; Huang WC; Huang CT; Chen CH; Yang JM
Sci Rep; 2015 Jun; 5():10938. PubMed ID: 26077136
[TBL] [Abstract][Full Text] [Related]
3. Extending kinome coverage by analysis of kinase inhibitor broad profiling data.
Jacoby E; Tresadern G; Bembenek S; Wroblowski B; Buyck C; Neefs JM; Rassokhin D; Poncelet A; Hunt J; van Vlijmen H
Drug Discov Today; 2015 Jun; 20(6):652-8. PubMed ID: 25596550
[TBL] [Abstract][Full Text] [Related]
4. Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches.
Gani OA; Thakkar B; Narayanan D; Alam KA; Kyomuhendo P; Rothweiler U; Tello-Franco V; Engh RA
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1605-16. PubMed ID: 26001898
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
6. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
Bauer SM; Kubiak JM; Rothbauer U; Laufer S
Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
[TBL] [Abstract][Full Text] [Related]
7. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.
Miljković F; Bajorath J
J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884
[TBL] [Abstract][Full Text] [Related]
8. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
Miduturu CV; Deng X; Kwiatkowski N; Yang W; Brault L; Filippakopoulos P; Chung E; Yang Q; Schwaller J; Knapp S; King RW; Lee JD; Herrgard S; Zarrinkar P; Gray NS
Chem Biol; 2011 Jul; 18(7):868-79. PubMed ID: 21802008
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery and the human kinome: recent trends.
Eglen R; Reisine T
Pharmacol Ther; 2011 May; 130(2):144-56. PubMed ID: 21256157
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.
Han W; Ding Y; Xu Y; Pfister K; Zhu S; Warne B; Doyle M; Aikawa M; Amiri P; Appleton B; Stuart DD; Fanidi A; Shafer CM
J Med Chem; 2016 Apr; 59(7):3034-45. PubMed ID: 27002243
[TBL] [Abstract][Full Text] [Related]
11. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
Thorarensen A; Kaila N
Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
[TBL] [Abstract][Full Text] [Related]
12. Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.
Miljković F; Vogt M; Bajorath J
J Comput Aided Mol Des; 2019 Jun; 33(6):559-572. PubMed ID: 30915709
[TBL] [Abstract][Full Text] [Related]
13. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
Hantschel O
ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles.
Kaila N; Green N; Li HQ; Hu Y; Janz K; Gavrin LK; Thomason J; Tam S; Powell D; Cuozzo J; Hall JP; Telliez JB; Hsu S; Nickerson-Nutter C; Wang Q; Lin LL
Bioorg Med Chem; 2007 Oct; 15(19):6425-42. PubMed ID: 17664070
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics of kinase inhibitor targets and mechanisms.
Daub H
ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
[TBL] [Abstract][Full Text] [Related]
16. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening.
Piala AT; Akella R; Potts MB; Dudics-Giagnocavo SA; He H; Wei S; White MA; Posner BA; Goldsmith EJ
Bioorg Med Chem Lett; 2016 Aug; 26(16):3923-7. PubMed ID: 27426302
[TBL] [Abstract][Full Text] [Related]
18. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
Bamborough P; Drewry D; Harper G; Smith GK; Schneider K
J Med Chem; 2008 Dec; 51(24):7898-914. PubMed ID: 19035792
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
